BioCentury
ARTICLE | Company News

Boehringer Ingelheim, Canbridge deal

August 22, 2016 7:00 AM UTC

Boehringer will manufacture Canbridge’s AV-203 ( CAN-017) in Shanghai. AV-203, an Erb-b2 receptor tyrosine kinase 3 ( ERBB3; HER3; EGFR3)-targeted antibody, completed Phase I testing to treat solid tumors. Earlier this year, Aveo Pharmaceuticals Inc. (NASDAQ:AVEO, Cambridge, Mass.) granted Canbridge exclusive, ex-North American rights to AV-203. ...